Maury Taylor - Hypertension Diagnostics Ex Director
| HDIIDelisted Stock | USD 0 0.0008 38.10% |
Insider
Maury Taylor is Ex Director of Hypertension Diagnostics
| Phone | 404-449-6151 |
| Web | https://www.hypertensiondiagnostics.com |
Hypertension Diagnostics Management Efficiency
Hypertension Diagnostics' management efficiency ratios could be used to measure how well Hypertension Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.Hypertension Diagnostics currently holds 4.69 M in liabilities. Hypertension Diagnostics has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Hypertension Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Hypertension Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hypertension Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hypertension to invest in growth at high rates of return. When we think about Hypertension Diagnostics' use of debt, we should always consider it together with cash and equity.
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada. Hypertension Diag operates under Shell Companies classification in the United States and is traded on OTC Exchange. Hypertension Diagnostics [HDII] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Hypertension Diagnostics is listed under Medical Equipment category by Fama And French industry classification. Management Performance
| Return On Asset | 3.0E-4 |
Hypertension Diagnostics Management Team
Elected by the shareholders, the Hypertension Diagnostics' board of directors comprises two types of representatives: Hypertension Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hypertension. The board's role is to monitor Hypertension Diagnostics' management team and ensure that shareholders' interests are well served. Hypertension Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hypertension Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph DAlbero, Exec | ||
| Liangjian Peng, Chief Officer | ||
| Maury Taylor, Ex Director |
Hypertension Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hypertension Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.0002 % | ||||
| Current Valuation | 5.26 M | ||||
| Shares Outstanding | 52.39 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Sales | 0.15 X | ||||
| Revenue | 3.79 M | ||||
| Gross Profit | 954.47 K | ||||
| EBITDA | 72.29 K |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |